ACADIA Pharmaceuticals (ACAD) AI Stock Analysis

• Market Cap: $4.55B
• Dividend Yield: N/A
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): 17.3
• Beta (1Y): 1.01
• Revenue Growth: 12.69%
• EPS Growth: 100.80%
• Country: US
• Employees: 653
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.42
• Shares Outstanding: 169,181,820
• 10 Day Avg. Volume: 1,086,105
• 30 Day Avg. Volume: 1,312,322
• PEG Ratio: -0.03
• Price to Book (P/B): 4.15
• Price to Sales (P/S): 3.17
• P/FCF Ratio: 19.34
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 2.72
• Enterprise Value/Gross Profit: 2.96
• Enterprise Value/Ebitda: 24.29
• 1Y Price Target: $31.15
• Price Target Upside: 15.76% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: $28.00 ▲(4.05% Upside)

ACADIA Pharmaceuticals is well-positioned with strong financial performance, robust technical indicators, and strategic growth initiatives. The company's reasonable valuation and positive earnings call sentiment further support its potential for future growth. However, operational efficiency improvements and market penetration challenges for DAYBUE remain areas to watch.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product sales, supporting long-term financial stability and expansion.

Pipeline Advancements

Ongoing pipeline advancements demonstrate ACADIA's commitment to innovation and potential for future revenue streams from new treatments.

Cash Position

A strong cash position provides financial flexibility for strategic investments and R&D, supporting long-term growth and stability.

Negative Factors

DAYBUE Market Penetration Challenges

Low market penetration for DAYBUE highlights challenges in gaining market share, which could impact revenue growth and long-term success.

R&D Expense Increase

Rising R&D expenses may strain profitability if not matched by revenue growth, affecting financial performance and investment capacity.

Disappointment in Canada

Challenges in securing reimbursement can limit market access and revenue potential, impacting international expansion efforts.

ACADIA Pharmaceuticals Business Overview & Revenue Model

Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

How the Company Makes Money

ACADIA Pharmaceuticals generates revenue primarily through the sales of its flagship product, NUPLAZID, which is marketed in the United States and other markets where it has received regulatory approval. The company employs a direct-to-consumer and direct-to-healthcare provider sales strategy, targeting neurologists and psychiatrists involved in the treatment of Parkinson's disease and related disorders. Additionally, ACADIA may engage in collaborations and partnerships with other pharmaceutical companies or research institutions to co-develop new therapies, which can provide milestone payments and royalties on future product sales. The company's revenue model is further supported by ongoing clinical trials and research that may lead to the expansion of its product portfolio with new indications or drugs, thus creating additional revenue streams.

ACADIA Pharmaceuticals Financial Statement Overview

Summary

ACADIA Pharmaceuticals demonstrates strong profitability and revenue growth, with significant improvements in net income and cash flow generation. The balance sheet reflects low leverage and a solid equity base, though there is room for enhancing operational efficiencies and cash flow conversion.

Income Statement

ACADIA Pharmaceuticals has shown a strong gross profit margin of over 91% consistently, indicating efficient cost management. The net profit margin has improved significantly, turning positive in the TTM period, reflecting enhanced profitability. Revenue growth is steady, with a notable increase in the TTM period. However, EBIT and EBITDA margins are relatively low, suggesting room for operational efficiency improvements.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating conservative leverage and financial stability. Return on equity has turned positive, showcasing improved profitability and shareholder returns. The equity ratio suggests a solid capital structure, though there is potential to optimize asset utilization further.

Cash Flow

Operating and free cash flows have improved, with positive growth rates indicating better cash generation capabilities. The operating cash flow to net income ratio is below 1, suggesting that not all net income is translating into cash flow, which could be a concern. However, the free cash flow to net income ratio is close to 1, indicating efficient cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.05B	957.80M	726.44M	517.24M	484.14M	441.75M
Gross Profit	962.54M	875.96M	680.71M	507.07M	465.00M	421.20M
EBITDA	117.30M	100.16M	-67.83M	-221.57M	-167.09M	-283.65M
Net Income	261.17M	226.45M	-61.29M	-215.97M	-167.87M	-281.58M
Balance Sheet
Total Assets	1.33B	1.19B	748.96M	587.81M	700.12M	782.62M
Cash, Cash Equivalents and Short-Term Investments	847.02M	755.99M	438.87M	416.82M	520.71M	631.96M
Total Debt	54.81M	51.99M	57.20M	62.00M	64.43M	49.55M
Total Liabilities	413.50M	454.96M	317.20M	187.40M	159.23M	155.61M
Stockholders Equity	917.27M	732.79M	431.75M	400.41M	540.89M	627.01M
Cash Flow
Free Cash Flow	197.81M	157.20M	-23.35M	-114.03M	-126.78M	-143.75M
Operating Cash Flow	198.95M	157.72M	16.70M	-114.03M	-125.66M	-136.17M
Investing Cash Flow	-124.55M	-30.54M	32.00M	73.24M	-71.10M	192.51M
Financing Cash Flow	29.19M	6.84M	25.13M	8.20M	18.16M	81.00M

ACADIA Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACAD, the sentiment is Positive. The current price of 26.91 is below the 20-day moving average (MA) of 27.06, above the 50-day MA of 25.27, and above the 200-day MA of 22.12, indicating a neutral trend. The MACD of 0.38 indicates Positive momentum. The RSI at 53.03 is Neutral, neither overbought nor oversold. The STOCH value of 63.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACAD.

ACADIA Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	79 Outperform	$7.22B	37.33	19.66%	―	54.51%	275.94%
ACAD	75 Outperform	$4.55B	17.31	34.95%	―	12.69%	100.80%
PTCT	68 Neutral	$6.17B	8.98	―	―	97.54%	―
ARWR	62 Neutral	$8.83B	-967.26	-0.50%	―	23258.15%	99.12%
MLTX	55 Neutral	$1.02B	-4.31	-54.17%	―	―	-157.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACLX	40 Underperform	$3.72B	-16.41	-47.18%	―	-76.96%	-425.41%